BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23322189)

  • 1. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Hare DJ; Adlard PA; Doble PA; Finkelstein DI
    Metallomics; 2013 Feb; 5(2):91-109. PubMed ID: 23322189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
    Wu KC; Liou HH; Lee CY; Lin CJ
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
    Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
    J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT; Luquín MR; Obeso JA
    Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
    Johannessen JN
    Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.
    Choi JY; Jang EH; Park CS; Kang JH
    Free Radic Biol Med; 2005 Mar; 38(6):806-16. PubMed ID: 15721991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
    Aoki E; Yano R; Yokoyama H; Kato H; Araki T
    Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental models, of Parkinson disease].
    Luquin MR
    Rev Neurol; 2000 Jul 1-15; 31(1):60-6. PubMed ID: 10948587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
    Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
    Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creatine and cyclocreatine attenuate MPTP neurotoxicity.
    Matthews RT; Ferrante RJ; Klivenyi P; Yang L; Klein AM; Mueller G; Kaddurah-Daouk R; Beal MF
    Exp Neurol; 1999 May; 157(1):142-9. PubMed ID: 10222117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.